Your Daily Pharma Scoop: Portola's New Interim Data, Lantheus Announces Promising Data For LMI 1195, Kura Tumbles On Update

Amarin (NASDAQ:AMRN) reported that in a post-hoc analysis of the ANCHOR study, patients with persistent high triglycerides (TG) and elevated high-sensitivity ... In 24 patients who received either a daily oral 2 mg or 8 mg dose of OPRX-106 for eight ...

TG Therapeutics (TGTX) Covered By H.C. Wainwright with $38.0 Target; Inovalon Holdings – Class A (INOV) Shorts Down By 2.43%

TG Therapeutics has $33 highest and $18 lowest target ... Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.